Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. by Adekar, Sharad P et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Biochemistry and Molecular Biology
Faculty Papers Department of Biochemistry and Molecular Biology
8-1-2008
Neutralization of botulinum neurotoxin by a
human monoclonal antibody specific for the
catalytic light chain.
Sharad P Adekar
Lankenau Institute for Medical Research, Wynnewood, PA
Tsuyoshi Takahashi
Division of Infectious Diseases and Environmental Medicine, Thomas Jefferson University, Philadelphia, PA
R Mark Jones
Department of Biochemistry and Molecular Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
Fetweh H Al-Saleem
Division of Infectious Diseases and Environmental Medicine, Thomas Jefferson University, Philadelphia, PA, Fetweh.Al-
Saleem@jefferson.edu
Denise M Ancharski
Division of Infectious Diseases and Environmental Medicine, Thomas Jefferson University, Philadelphia, PA
See next page for additional authorsLet us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/bmpfp
Part of the Medical Biochemistry Commons, Medical Microbiology Commons, Medical
Pathology Commons, and the Neurosciences Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Biochemistry and Molecular Biology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more
information, please contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Adekar, Sharad P; Takahashi, Tsuyoshi; Jones, R Mark; Al-Saleem, Fetweh H; Ancharski, Denise M;
Root, Michael J; Kapadnis, B P; Simpson, Lance L; and Dessain, Scott K, "Neutralization of
botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain."
(2008). Department of Biochemistry and Molecular Biology Faculty Papers. Paper 32.
http://jdc.jefferson.edu/bmpfp/32
Authors
Sharad P Adekar, Tsuyoshi Takahashi, R Mark Jones, Fetweh H Al-Saleem, Denise M Ancharski, Michael J
Root, B P Kapadnis, Lance L Simpson, and Scott K Dessain
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/bmpfp/32
Neutralization of Botulinum Neurotoxin by a Human
Monoclonal Antibody Specific for the Catalytic Light
Chain
Sharad P. Adekar1, Tsuyoshi Takahashi2, R. Mark Jones3, Fetweh H. Al-Saleem2, Denise M. Ancharski2,
Michael J. Root3, B. P. Kapadnis4, Lance L. Simpson2, Scott K. Dessain1*
1 Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, United States of America, 2Division of Infectious Diseases and Environmental Medicine, Thomas
Jefferson University, Philadelphia, Pennsylvania, United States of America, 3Department of Biochemistry and Molecular Biology, Kimmel Cancer Center, Thomas Jefferson
University, Philadelphia, Pennsylvania, United States of America, 4Department of Microbiology, University of Pune, Pune, India
Abstract
Background: Botulinum neurotoxins (BoNT) are a family of category A select bioterror agents and the most potent
biological toxins known. Cloned antibody therapeutics hold considerable promise as BoNT therapeutics, but the therapeutic
utility of antibodies that bind the BoNT light chain domain (LC), a metalloprotease that functions in the cytosol of
cholinergic neurons, has not been thoroughly explored.
Methods and Findings: We used an optimized hybridoma method to clone a fully human antibody specific for the LC of
serotype A BoNT (BoNT/A). The 4LCA antibody demonstrated potent in vivo neutralization when administered alone and
collaborated with an antibody specific for the HC. In Neuro-2a neuroblastoma cells, the 4LCA antibody prevented the
cleavage of the BoNT/A proteolytic target, SNAP-25. Unlike an antibody specific for the HC, the 4LCA antibody did not block
entry of BoNT/A into cultured cells. Instead, it was taken up into synaptic vesicles along with BoNT/A. The 4LCA antibody
also directly inhibited BoNT/A catalytic activity in vitro.
Conclusions: An antibody specific for the BoNT/A LC can potently inhibit BoNT/A in vivo and in vitro, using mechanisms not
previously associated with BoNT-neutralizing antibodies. Antibodies specific for BoNT LC may be valuable components of
an antibody antidote for BoNT exposure.
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Introduction
Botulinum neurotoxins (BoNTs) are a family of category A
select bioterror agents and the most potent biological toxins known
[1]. BoNTs are produced by bacteria of the genus Clostridium and
are the cause of the paralytic disease, botulism. BoNT exposure
can occur either by respiratory or gastrointestinal routes.
Clinically, exposure to BoNT results in a flaccid peripheral and
bulbar paralysis that can require weeks to months of ventilatory
and intensive care unit support. BoNT has been prepared for use
as a bioweapon by governments as well as a terrorist organization.
An estimate of the possible effects of an intentional environmental
release of BoNT predicted 10% incapacitation or death for those
within 0.5 km down-wind of the release site [1]. In addition, the
U.S. milk supply may be particularly vulnerable to a terrorist
attack with BoNT [2].
BoNTs exist in seven serotypes (A–G), each of which has distinct
antigenic and functional attributes. However, every BoNT is a
heteromeric molecule that consists of a 100 kD heavy chain
domain (HC) and a 50 kD light chain domain (LC). The steps of
BoNT intoxication have been well defined [3]. The HC portion of
the toxin mediates binding to cholinergic nerve synapses. BoNT
binding to neurons involves recognition of low affinity ganglioside
binding sites as well as high affinity protein binding sites, such as
SV2, the synaptic vesicle protein recognized by serotype A BoNT
(BoNT/A) [4,5]. Once bound, the toxin enters the neurons by
endocytosis. This is followed by acidification of the endosomes,
which induces translocation of the LC into the cytosol, in a process
that is facilitated by the HC [3]. In the cytosol, the LC domains
use a zinc metalloprotease activity to cleave components of the
SNARE (soluble N-ethylmaleimide-sensitive factor attachment
protein receptor) complex, a set of proteins required for synaptic
vesicle fusion and the release of the neurotransmitter acetylcholine.
One of the SNARE proteins, the synaptosomal-associated 25 kDa
protein (SNAP-25), is specifically cleaved and inactivated by the
BoNT/A LC, which removes a 9-amino acid C-terminal peptide
[6]. As a consequence, acetylcholine cannot be released into the
neuromuscular synapse and paralysis results.
Immunotherapy is presently considered to be the most effective
immediate response to BoNT exposure, but the human anti-BoNT
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antiserum (BabyBIG) is in very limited supply and equine antisera
can induce serum sickness and anaphylaxis [1,7]. Monoclonal
antibodies may be a viable substitute for polyclonal antisera [8,9].
An important principle is that combinations of antibodies
synergistically cooperate in neutralization potency [10]. Kinetic
studies have shown that a BoNT/A-specific triplex antibody
combination exhibits cooperative binding to the toxin, increasing
the stability of the antibody:toxin complex [10]. Epitope mapping
has shown that the three antibodies together cover a large region
of the surface of the BoNT/A HC domain required for neuron
binding [11]. In addition, pharmacokinetic studies have demon-
strated that immune complexes formed in the blood circulation
between BoNT and polyclonal antisera rapidly sequester the toxin
in the liver and spleen [12].
A majority of the effort to create combinations of antibodies for
use as BoNT therapeutics has concentrated on antibodies that
bind the HC. These antibodies can potentially inhibit the
interaction of BoNT with its neuron receptors [8,13]. We explored
the potential for an antibody directed at the LC to neutralize toxin
in vitro and in vivo. We recently described a novel hybridoma
method for cloning human antibodies [14,15]. We have used this
method to clone a fully human antibody specific for the BoNT/A
LC. We have found that it has novel features that enable it to
potently neutralize BoNT/A in vivo and in vitro.
Results
A human antibody specific for the botulinum neurotoxin
serotype A light chain catalytic domain
We obtained peripheral blood from a volunteer on the 8th day
following a fifth dose of the pentavalent botulinum toxoid vaccine.
The mononuclear cell population was purified by Ficoll gradient
centrifugation and cells expressing the CD27 antigen were isolated
by magnetic beads conjugated to an anti-CD27 antibody. The
selected cells were cultured for 8 days over a monolayer of
irradiated tCD40L fibroblast cells, which express the human
CD40 ligand, in culture medium that contained interleukin-4,
interleukin-10, and cyclosporine [14,16]. The cultured cells were
fused to the B5-6T cell line, a human-murine hybrid myeloma cell
that expresses the hTERT and mIL-6 genes [17]. After HAT
selection, a hybridoma expressing an antibody reactive with
bacterially expressed BoNT/A light chain was identified and
subcloned by limiting dilution three times.
By ELISA, the 4LCA antibody binds specifically to the BoNT/A
LC, and not to the BoNT/A heavy chain (data not shown). We used
the kinetic exclusion assay (KinExA) to measure the binding affinity
of the 4LCA antibody for the BoNT/A LC (Figure 1). Equilibrium
binding analysis measured a KD value of 3165610
212 M, with a
kon value of 2.360.1610
6 M21 s21. The calculated koff value of
7.161025 s21 estimates an average bound lifetime of a 4LCA/LC
complex to be ,4 hours at room temperature.
The 4LCA antibody is comprised of an IgG1 heavy chain and a
lambda light chain (data not shown). We obtained the sequence of
the heavy chain and light chain variable domains of the 4LCA
antibody, using RT-PCR with consensus primers to amplify these
domains (Table 1) [14]. The heavy chain is derived from the V4-
39*01 gene, with 16 mutations in its variable domain, and the light
chain uses the V3-21*01 gene, with 11 mutations. These are
consistent with an origin of the antibody within a CD27+, post-
germinal center B-cell.
Neutralizing activity of the 4LCA antibody in vivo
We tested the ability of 4LCA to neutralize BoNT in the
standard mouse protection assay. We incubated 100 mg 4LCA
with BoNT/A for 1 hour prior to intravenous injection into Swiss
Webster mice, testing groups of 6 mice at each dose level. Mice
were observed for morbidity and mortality over 30 days. Complete
Figure 1. Kinetic exclusion analysis (KinExA) of the solution
binding properties of the 4LCA antibody and BoNT/A LC. (A)
The equilibrium binding affinity was determined by titrating recombi-
nant BoNT/A LC into solutions of fixed 4LCA concentration. At
equilibrium, free 4LCA was captured by passage through a bead matrix
conjugated to LC and measured by binding of a fluorescent secondary
antibody. The data were fit using the manufacturer’s software to a
bimolecular binding model, giving an optimized KD value of
3165610212 M. (B) The association rate constant (kon) was measured
by mixing 4LCA (200 pM) with LC (10 pM) and measuring the
concentration of free antibody concentration over time. The average
kon value for 4LCA was estimated to be 2.360.1610
6 M21 s21, which
gives a calculated koff value of 7.1610
25 s21.
doi:10.1371/journal.pone.0003023.g001
Table 1. 4LCA variable domain usage, CDR3 sequences, and
mutation status.
V-gene J-gene D-gene CDR3 sequence
CDR3
length Muts
IgG HC V4-39*01 J5*02 D3-16*01 ATFLGRGAPFDP 12 20
IgG LC V3-21*01 J3*02 N/A QVWGSGSDHPGV 12 11
CDR3, complementary determining region 3. Muts, mutations in the entire IgG
HC and LC variable domains.
doi:10.1371/journal.pone.0003023.t001
BoNT/A LC Human Antibody
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protection was observed with doses up to 25 LD50s, which exceeds
by 10-fold the 2.5 LD50s that we had previously shown could be
neutralized by the 6A antibody, a human IgG specific for the
BoNT/A heavy chain (Table 2) [14]. Partial protection, as
indicated by increased survival compared to antibody-free control
mice, was afforded with higher doses (Table 2). At 100 LD50s,
mice receiving 4LCA survived 85 hours, compared to 8 hours for
the control mice, and at 250 LD50, 4LCA mice survived 40 hours,
compared to 4 hours for the control mice. As combinations of
monoclonal antibodies have demonstrated synergy in BoNT/A
neutralization [8], we next tested for synergy with the 6A
antibody. We mixed 50 mg each of the 4LCA and 6A antibodies
(total of 100 mg) with 1,000 LD50s BoNT/A and tested the
combination by intravenous injection. In two separate experi-
ments, all of the mice that received the antibodies survived, in
contrast to the control mice, which died in less than 3 hours.
Neutralization of BoNT activity by the 4LCA antibody
We analyzed the neutralization activity of the 4LCA antibody
using cell culture and enzymatic assays. In the first assay, we tested
the ability of the 4LCA to inhibit cleavage of SNAP-25, the
proteolytic substrate of the BoNT/A LC, in Neuro-2a murine
neuroblastoma cells [18,19]. Cleavage of SNAP-25 by the BoNT/
A LC removes 9 C-terminal amino acids, resulting in a truncated
form of SNAP-25 that can be detected by immunoblotting. We
compared the 4LCA and 6A antibodies with the 15A antibody,
which binds BoNT/A with low affinity and has no neutralizing
activity in vivo (data not shown). We incubated 2 mg of BoNT/A
with 500 mg of human monoclonal antibody and then applied the
mixtures to Neuro-2a cell monolayers. After 48 hours, whole-cell
extracts were assayed by immunoblotting with an antibody specific
for SNAP-25. As shown in Figure 2a, exposure of the cells to
BoNT/A alone resulted in the appearance of the proteolytic
cleavage product. The 15A (non-neutralizing) antibody had no
effect. In contrast, the 4LCA and 6A antibodies inhibited 92% and
84% of the cleavage induced by BoNT/A, respectively (Figure 2a
and 2b). When administered together, the 4LCA and 6A had a
combined effect that completely inhibited SNAP-25 cleavage
(Figure 2a and 2b). Thus, the in vivo neutralizing activity of the
4LCA and 6A antibodies is correlated with the ability of the
antibodies to inhibit SNAP-25 cleavage in a cultured cell line.
Because the 4LCA directly binds to the BoNT/A LC, we
assessed whether it can inhibit the catalytic function of the LC. We
used a fluorescence resonance energy transfer assay (FRET),
which measures cleavage of a synthetic SNAP-25 peptide
(SNAPtide) [20]. The SNAPtide is conjugated to FITC and
DABCYL, a molecule that quenches the fluorescent FITC
emission. Cleavage of the peptide un-quenches the FITC signal,
which can then be measured as an indicator of metalloprotease
activity. We incubated the 4LCA and 6A antibodies with the
SNAPtide in triplicate reactions and measured the FITC
fluorescence intensity (Figure 3). The 6A antibody did not
interfere with cleavage of the SNAPtide, giving 26 fluorescence
units (FIU), compared to 30 FIU for the control, whereas the
4LCA antibody inhibited SNAPtide cleavage, giving 11 FIU.
Thus, binding of the 4LCA antibody can directly inhibit BoNT/A
metalloprotease activity.
BoNT/A-dependent internalization of the 4LCA antibody
by Neuro-2a cells
BoNT-specific antibodies with neutralization capability may
directly impair the interaction of toxin with its target cells [11]. We
tested the effect of the 4LCA and 6A antibodies on the interaction
of BoNT/A with Neuro-2a cells. We labeled the 4LCA and 6A
antibodies with DyLight 549 and BoNT/A with DyLight 488 and
examined the cells using confocal microscopy (Figure 4). BoNT/A
was taken up by the Neuro-2a cells in a punctate pattern consistent
with internalization within endocytosed synaptic vesicles [21]
(Figure 4A). When BoNT/A was co-incubated with the 6A
antibody, uptake of BoNT/A by the Neuro-2a cells was
completely prevented (Figure 4B), consistent with the specificity
of the 6A antibody for the BoNT/A 50 kD C-terminal, neuron-
binding domain [14]. The 4LCA antibody did not prevent
internalization of the BoNT/A. Instead, it appeared to enter the
cells, giving signals that overlapped with the labeled BoNT/A
(Figure 4C). No 4LCA signals were observed that did not co-
Table 2. BoNT neutralization activity of the 4LCA human
monoclonal antibody in the mouse protection assay.
huMAb BoNT/A LD50
Survival time
hours
Survival
alive/tested
Control 25 8 0/6
4LCA 25 * 6/6
6A 25 24 0/6
Control 100 ,8 0/6
4LCA 100 85 0/6
Control 250 ,4 0/6
4LCA 250 40 0/6
Control 1000 ,3 0/6
4LCA+6A 1000 * 6/6
*mice were healthy at 30 days.
doi:10.1371/journal.pone.0003023.t002
Figure 2. Effect of human antibodies on cleavage of SNAP-25
by BoNT/A in Neuro-2a cells. Neuro-2a cells were incubated with
BoNT/A for 48 hours in the presence or absence of human antibody. (A)
Cleavage of SNAP-25 was detected by immunoblotting of whole cell
extracts. Removal of a 9 amino acid C-terminal fragment gives a band of
reduced size (Cleaved) in addition to an intact SNAP-25 band
(Uncleaved). Cells received either the antibodies indicated or culture
medium without antibody (M). (B) The extent of SNAP-25 cleavage in
the experiment shown in Figure 2A was quantified by scanning
densitometry. Values are reported normalized to the cell sample that
contained BoNT/A but no antibody.
doi:10.1371/journal.pone.0003023.g002
BoNT/A LC Human Antibody
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localize with BoNT/A signals, even though the 4LCA was in 500-
fold molar excess compared to BoNT/A. This indicates that the
entry of the 4LCA into the Neuro-2a cells was dependent on its
binding to BoNT/A.
Discussion
In the present study, we cloned and characterized the first fully
human monoclonal antibody specific for the BoNT/A LC. The
4LCA antibody is an IgG1 l antibody with picomolar binding
affinity. It demonstrated a potent neutralizing activity in vivo, with
10-fold more activity than the 6A antibody, which binds the
BoNT/A HC and is the most potent fully human BoNT/A
neutralizing antibody previously described. An equimolar combi-
nation of the 6A and 4LCA antibodies was able to neutralize
BoNT/A with a potency of 10,000 LD50/mg antibody. This
potency is over three times greater than the BoNT/A neutrali-
zation standard devised for the commercially available BabyBig
human anti-BoNT antiserum (3,000 LD50/mg antibody) [22].
These results indicate that the antibodies that bind the BoNT/A
LC can have significant neutralizing abilities and should be useful
components of oligoclonal antibody therapeutics for BoNT
exposures.
As would be expected with a neutralizing antibody specific for
the HC, the 6A antibody completely inhibited endocytosis of the
toxin by Neuro 2a cells. In contrast, the 4LCA antibody was
endocytosed along with BoNT/A and co-localized with the BoNT
within intracellular vesicles. Thus, the 4LCA appears to inhibit
toxin function at the final stages of the intoxication process, after
BoNT enters the cell and before it cleaves its intracellular
substrate, SNAP-25. The ability of an antibody to neutralize
BoNT at an intracellular level has not previously been described.
A number of mechanisms may account for this activity, but it is
most likely that the antibody causes the LC to be retained within
endosomes. Fisher and Montal observed that an LC-specific Fab
antibody prevented translocation of the BoNT/A LC across a
model endosomal plasma membrane [23]. In such a case, the
4LCA antibody may force the return of the BoNT to the cell
surface through synaptic vesicle recycling [21]. A similar
phenomenon was observed with the A subunit of the Shiga Toxin
2 (Stx2), which normally undergoes transit from early endosomes
to the Golgi and endoplasmic reticulum. Binding of Stx2 to a
neutralizing antibody caused recycling of the bound toxin back to
the cell membrane [24].
The 4LCA antibody was also able to inhibit the catalytic activity
of BoNT/A in an in vitro assay with a synthetic substrate. This
capability is not a feature common to all LCA-specific antibodies,
since a polyclonal rabbit anti-BoNT/A antiserum, immunoreactive
with the BoNT/A LC, did not affect the cleavage of the SNAPtide
(Supplemental Figure S2 in [25]). In its native state, BoNT/A
contains a ‘‘translocation domain belt’’, which occupies much of the
SNAP-25 binding and catalytic site of the LC domain [26]. Binding
of the 4LCA antibody to the holotoxin is apparently not inhibited by
the presence of the translocation domain belt, as it binds the BoNT/
A holotoxin with approximately the same affinity as it does to the
recombinant LC (data not shown). This suggests that the 4LCA
antibody binds the LC at a site independent of the SNAP-25
Figure 3. Inhibition of the catalytic activity of the BoNT/A
metalloprotease by the 4LCA antibody in vitro. In this fluores-
cence resonance energy transfer assay (FRET), cleavage of the SNAPtide
by BoNT/A LC un-quenches FITC fluorescence, which is quantified as
arbitrary fluorescence units. In triplicate samples, the SNAPtide was
incubated with BoNT/A alone or with the 6A or 4LCA antibodies and
fluorescence was measured. Standard deviation (s.d.) is indicated by
error bars.
doi:10.1371/journal.pone.0003023.g003
Figure 4. The effect of BoNT/A-specific antibodies on endocytosis of BoNT/A by Neuro-2a cells. Neuro-2a cells were cultured with
fluorescently-labeled BoNT/A (red), with or without human antibody (green), and visualized by confocal microscopy. Panel (A) No antibody. (B) 6A
antibody. (C) 4LCA antibody. In each panel, 4 images of each field are shown: BoNT/A (BT), Antibody (AB), merged (M), and phase contrast (P).
doi:10.1371/journal.pone.0003023.g004
BoNT/A LC Human Antibody
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substrate binding site and therefore may inhibit the LC by a non-
competitive mechanism. Because the antibody-bound BoNT
appears to be trapped in endocytic vesicles, it is not yet clear
whether the ability of the 4LCA antibody to inhibit LC catalytic
function can contribute to its neutralization potency in vivo.
A theoretical advantage to the inclusion of a light chain-specific
antibody in an oligoclonal antibody therapeutic is that it provides
an additional layer of protection from BoNT, intracellular
neutralization, at the same time as it contributes to clearance of
the toxin by immune complex-mediated mechanisms. Because a
BoNT/A therapeutic cannot be thoroughly tested in humans in a
non-emergency setting, it will be important to increase the
confidence in the efficacy of a BoNT/A antitoxin by incorporating
antibodies with as many complementary neutralizing functions as
possible. In this context, the light chain is an important target
because it offers an ability to inhibit a BoNT/A molecule that has
evaded neutralization at the level of toxin uptake, bloodstream
circulation, and neuron binding.
A wide variety of bacterial toxins have catalytic domains that
enter cells through the aid of heteromeric sub-units [27]. Because
the 4LCA antibody was cloned from a human subject, it is clear
that the human immune system can generate a significant
neutralizing response against the BoNT catalytic domain. The
use of human antibodies specific for the catalytic domains of
bacterial toxins may be an important general principle in the
development of effective anti-toxins. Finally, the study of these
antibodies may provide insights into the way endocytosed proteins
are processed by cells, as well as how toxins could be used to
deliver drugs or peptides to membranous organelles within a cell.
Materials and Methods
Cell culture and 4LCA antibody cloning
Peripheral blood lymphocytes were obtained from a volunteer
donor 8 days following a fifth dose of the pentavalent botulinum
toxoid vaccine, following a protocol approved by the Institutional
Review Board of the Thomas Jefferson University. The peripheral
blood mononuclear cell (PBMC) fraction was isolated using
gradient density centrifugation with FicollPaque PLUS (GE
Healthcare, Piscataway, NJ) and stored under liquid nitrogen in
90% heat-inactivated fetal calf serum (Invitrogen, Carlsbad, CA)
10% DMSO (Sigma-Aldrich, St. Louis, MO). For cell fusion,
16107 PBMCs were thawed and CD27+ cells were selected using
magnetic beads (Miltenyi Biotec, Auburn, CA) and then cultured
on a monolayer of irradiated tCD40L cells (courtesy of Gordon
Freeman, Dana Farber/Partners Cancer Care, Boston, MA), in
IMDM supplemented with 10% human serum, IL-4 (2 ng/ml),
IL-10 (10 ng/ml), transferrin (50 mg/ml), cyclosporine A
(5.561024 M), L-glutamine (2 mM), BoNT/A or HC50A (5 mg/
ml) and penicillin/streptomycin (Sigma-Aldrich). After 8 days of
culture, 56105 cells were fused with 56105 B5-6T cells and plated
in 2696-well plates over a C57BL/6 thymocyte feeder layer. HAT
selection was initiated 24 hours after cell fusion and continued for
7 days. Hybridoma pools were screened on day 10 for IgG reactive
with the BoNT/A LC and a positive pool was subcloned 3 times to
isolate a stable hybridoma expressing the 4LCA antibody. The
hybridoma was adapted to serum-free IS MAB-CD (Irvine
Scientific, Santa Ana, CA), and cultured for 5 days in a 500 ml
roller bottle at an initial density of 56105 cells/ml in 100 ml
culture. Supernatants were filtered and antibodies were purified
over a Protein G Sepharose column (GE Healthcare). SDS-PAGE
(Invitrogen) and the NanoDrop spectrophotometer (NanoDrop
Technologies, Wilmington, DE) were used to assess antibody
purity and concentration.
ELISAs
BoNT/A LC-specific antibodies were identified by ELISA with
a recombinant LC, in the form of a recombinant N-terminal
domain of BoNT/A (amino acids 1–425), which was produced in
E. coli and purified following published protocols [28]. EasyWash
96-well plates (Corning) were coated at 4 C overnight with
100 ml/well recombinant BoNT/A LC (at 5 mg/ml) in PBS,
washed with PBS/0.05% Tween-20 (Sigma-Aldrich) and then
blocked for 1 hour at 37 C with PBS/0.05% Tween-20/5%
bovine calf serum/3% goat serum (Sigma-Aldrich). 100 ml
hybridoma supernatants were incubated for 2 hours at 37 C,
and an HRP-conjugated murine anti-human IgG secondary
antibody was used (9040-05, Southern Biotechnology, Birming-
ham, AL) with OPD as a substrate (Sigma-Aldrich) to detect
bound human IgG. The 4LCA lambda light chain and the IgG1
subtype were identified with the HRP-conjugated specific goat
polyclonal antibody A5175 (anti-lambda) and the mouse mono-
clonal I9388 (anti-human IgG1) (both from Sigma-Aldrich).
RT-PCR amplification of antibody genes
The variable domain sequences of the 4LCA heavy and light
chain genes were amplified using RT-PCR with consensus primer
sets as described previously [14,29,30]. RNA was isolated from
hybridoma using RNA Stat 60 (Tel-Test, Inc., Friendswood, TX).
Reverse transcriptase reactions were performed with Omniscript
RT (Qiagen, Valencia, CA). PCR reactions were performed with
Taq (Qiagen, Valencia), for 30 cycles of 94 C, 15 sec; 55 C,
30 sec; 72 C, 60 sec. Amplified sequences were isolated by agarose
gel electrophoresis, purified using the QiaQuick Gel Extraction kit
(Qiagen), and sequenced by the Kimmel Cancer Center Nucleic
Acid Facility, Thomas Jefferson University. DNA sequences were
analyzed using the V-Quest program [31].
Binding measurements
To determine the solution-phase binding affinity of the 4LCA
antibody, recombinant BotN/T A LC was titrated into solutions
containing a fixed concentration of antibody. All experiments were
performed at room temperature. Samples were prepared in Tris-
buffered saline (50 mM Tris, 100 mM NaCl, pH 8) supplemented
with 1 mMPMSF, 0.02%NaN3 and 1 mg/ml BSA. At equilibrium,
each solution was passed through the flow cell of a KinExA 3000
flow fluorimeter (Sapidyne Instruments, Boise, ID), and free
(unbound) 4LCA mAb was captured using LC covalently coupled
to azlactone beads (,36 mm average size, Pierce Biotechnology,
Rockford, IL) [32]. Beads were prepared by incubating 100 mg
activated azlactone (Pierce) and 50 mg LC overnight in 1 ml sodium
carbonate buffer (50 mM, pH 9) at 4 C, and subsequently blocked
by the addition of 150 mg BSA (Sigma-Aldrich). Captured antibody
was detected using a rhodamine-labeled, goat-anti-human second-
ary antibody (Jackson ImmunoResearch, West Grove, PA). The
fluorescent signals from multiple titrations were fit to a general
bimolecular interaction model (manufacturer’s software) that
assumes a known concentration of 4LCA mAb, enabling the
determination of both an equilibrium dissociation constant (KD) and
the LC specific activity [33]. For some nonequilibrated 4LCAmAb/
LC mixtures, the time course of the association reaction was
followed in a similar manner in order to determine an association
rate constant (kon) [17]. The dissociation rate constant (koff) was
calculated using the relationship koff =KD6kon.
Cell culture-based neutralization assay
In vitro neutralization of BoNT by human monoclonal
antibodies was assayed with the murine cholinergic neuroblastoma
BoNT/A LC Human Antibody
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cell line Neuro-2a (CCL-131; ATCC, Manassas, VA). Neuro-2a
cells were plated at 56104 per well in a 24-well tissue culture plate
in Opti-MEM with 1% IFS, glutamine and pen/strep (Invitrogen).
After 48 hours, the medium was replaced with serum-free Opti-
MEM and cells were incubated for an additional 24 hours. 2 mg
BoNT/A was incubated with 500 mg antibody in 1 ml serum-free
Opti-MEM for 1 hour at room temperature. The mixture was
added to the Neuro-2a cells, which were then incubated for
48 hours. Cells were separated from the plates mechanically,
boiled for 10 minutes in 16 NuPAGE LDS sample buffer and
separated by SDS/PAGE on a 12% Bis-Tris NuPAGE gel in
MOPS/SDS running buffer (Invitrogen). Proteins were trans-
ferred to 0.2 mm Hybond ECL membrane (GE Healthcare,
Piscataway, NJ) and the membrane was soaked in blocking buffer
(5% skim milk/PBS) overnight at 4 C. An anti-SNAP-25 mouse
monoclonal IgG1 (Santa Cruz Biotechnology, Santa Cruz, CA)
was used as the primary antibody, diluted 1:1000 into blocking
buffer and added to blot for 1 hr at room temperature. After
washing, the blot was probed for 1 hour with a goat anti-mouse
HRP-conjugated secondary antibody (Thermo Scientific, Rock-
ford, IL) at 1:10,000 dilution and then developed with Super-
Signal West Dura Chemiluminescent Substrate (Pierce). Quanti-
tation of the Western blot analysis was done by densitometric
analysis with a Kodak imager.
Fluorescence resonance energy transfer (FRET) assay
The effect of human antibodies on the endopeptidase activity of
the BoNT/A LC was measured using fluorescent resonance
energy transfer assay with the SNAPtide, a synthetic SNAP-25
cleavage site peptide conjugated to two fluorescent molecules
(fluorescein thiocarbamoyl (FITC), and 4-(dimethylaminoazo)
benzene-4-carboxyl (DABCYL) [20] (List Biological Laboratories,
Inc., Campbell, CA). Cleavage of the peptide by the LC relieves
the intramolecular quenching by the FITC and DABCYL
moieties. Triplicate reactions of BoNT/A (5 nM) and human
monoclonal antibody (30 mM) were mixed in 100 ml reaction
volumes, which also contained 20 mM HEPES buffer, pH 8.0,
0.3 mM ZnCl2, 1.25 mM DTT and 0.1% Tween-20, pH 8.0.
Assay mixtures were incubated for 30 minutes at room temper-
ature, SNAPtide (5 mM) was added, and the mixtures were
incubated for two additional hours at 37 C. Samples were
transferred to a Corning CoStar black 96-well microtiter plate
(Fisher Scientific, Pittsburgh, PA) and mixed with 200 ml EDTA
20 mM. Fluorescence intensity of each sample was measured with
a Biotek Synergy-HT spectrophotometer at excitation and
emission wavelengths of 485 nm and 523 nm, respectively.
Confocal microscopy
BoNT/A was labeled with the DyLight 549 microscale antibody
labeling kit and the human monoclonal antibodies (6A, 4LCA)
were labeled with the DyLight 488 microscale antibody labeling
kit (both from Pierce Biotechnology). Labeled BoNT/A (1 mg) was
incubated with control medium or monoclonal antibody (500 mg
4LCA or 6A) for one hour at room temperature. Sub-confluent
Neuro-2a cells, plated on glass cover slips, were incubated with the
BoNT mixtures at 4 C for one hour and then for 2 hours at 37 C.
Cells were then washed with PBS for 15 minutes, fixed with 4%
paraformaldehyde for 15 mins, and washed again before mount-
ing. Confocal laser scanning was performed on a Olympus
Fluoview 500 system using the 406 objective, and Fluoview
software was used for image analysis.
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